Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryce Chackerian

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
NPJ Vaccines|May 13, 2025
pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy modelJonathan P Hulse, Nicole M Maphis, Julianne Peabody, et al.
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|March 12, 2014
Targeted immunomodulation using antigen-conjugated nanoparticlesDerrick P McCarthy, Zoe N Hunter, Bryce Chackerian, et al.
Antiviral Research|September 24, 2017
A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9Lukai Zhai, Julianne Peabody, Yuk-Ying Susana Pang, et al.
Vaccine|June 26, 2014
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingMitchell Tyler, Ebenezer Tumban, Agnieszka Dziduszko, et al.
BMC Neuroscience|June 10, 2004
Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic miceQingyou Li, Chuanhai Cao, Bryce Chackerian, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|January 13, 2010
Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvantQing-you Li, Marcia N Gordon, Bryce Chackerian, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Minimal determinants for lifelong antiviral antibody responses in BALB/c mice from a single exposure to virus-like immunogens at low dosesWei-Yun Wholey, Alexander R Meyer, Sekou-Tidiane Yoda, et al.
Vaccines|April 27, 2024
Minimal Determinants for Lifelong Antiviral Antibody Responses in Mice from a Single Exposure to Virus-like Immunogens at Low DosesWei-Yun Wholey, Alexander R Meyer, Sekou-Tidiane Yoda, et al.
Molecular Pharmaceutics|March 29, 2016
Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human PapillomavirusSugandha Saboo, Ebenezer Tumban, Julianne Peabody, et al.
Plos One|November 8, 2014
Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathwayJohn P O'Rourke, Seth M Daly, Kathleen D Triplett, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
NPJ Vaccines|May 13, 2025
pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy modelJonathan P Hulse, Nicole M Maphis, Julianne Peabody, et al.
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|March 12, 2014
Targeted immunomodulation using antigen-conjugated nanoparticlesDerrick P McCarthy, Zoe N Hunter, Bryce Chackerian, et al.
Antiviral Research|September 24, 2017
A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9Lukai Zhai, Julianne Peabody, Yuk-Ying Susana Pang, et al.
Vaccine|June 26, 2014
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingMitchell Tyler, Ebenezer Tumban, Agnieszka Dziduszko, et al.
BMC Neuroscience|June 10, 2004
Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic miceQingyou Li, Chuanhai Cao, Bryce Chackerian, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|January 13, 2010
Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvantQing-you Li, Marcia N Gordon, Bryce Chackerian, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Minimal determinants for lifelong antiviral antibody responses in BALB/c mice from a single exposure to virus-like immunogens at low dosesWei-Yun Wholey, Alexander R Meyer, Sekou-Tidiane Yoda, et al.
Vaccines|April 27, 2024
Minimal Determinants for Lifelong Antiviral Antibody Responses in Mice from a Single Exposure to Virus-like Immunogens at Low DosesWei-Yun Wholey, Alexander R Meyer, Sekou-Tidiane Yoda, et al.
Molecular Pharmaceutics|March 29, 2016
Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human PapillomavirusSugandha Saboo, Ebenezer Tumban, Julianne Peabody, et al.
Plos One|November 8, 2014
Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathwayJohn P O'Rourke, Seth M Daly, Kathleen D Triplett, et al.
Pageof 10